# A Randomized Study of Testosterone Replacement in Patients With Low Risk Hormone Refractory Prostate Cancer

> **NCT01187485** · PHASE1 · COMPLETED · sponsor: **University of Chicago** · enrollment: 15 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Androderm® 2.5mg
- **DRUG:** Androderm® 5.0mg
- **DRUG:** Androderm® 7.5mg

## Key facts

- **NCT ID:** NCT01187485
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** 2008-02
- **Final completion:** 2009-02
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2023-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01187485

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01187485, "A Randomized Study of Testosterone Replacement in Patients With Low Risk Hormone Refractory Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01187485. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*